July 6, 2020 / 5:43 AM / a month ago

BRIEF-Gensight To Submit Lumevoq For Marketing Authorisation in EU

July 6 (Reuters) - GENSIGHT BIOLOGICS SA:

* GENSIGHT BIOLOGICS REPORTS SUSTAINED EFFICACY AND SAFETY AMONG LHON PATIENTS THREE YEARS AFTER LUMEVOQ® TREATMENT

* NEW DATA WILL REINFORCE SUBMISSION OF LUMEVOQ® FOR MARKETING AUTHORIZATION IN EUROPEAN UNION, WHICH IT INTENDS TO FILE IN SEPTEMBER 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below